MannKind Corporation and BIOMM SA announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil. Under the supply and distribution agreement, Biomm will be responsible for preparing and filing the necessary applications for regulatory approval of Afrezza, including from the Agência Nacional de Vigilância Sanitária and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos. Upon satisfactory approval from these regulatory bodies, MannKind will manufacture and supply Afrezza to Biomm, and Biomm will be responsible for promoting and distributing Afrezza within Brazil.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.6 USD | +3.37% | +6.73% | +26.37% |
May. 08 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.37% | 1.21B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- MNKD Stock
- News MannKind Corporation
- MannKind Corporation and Biomm Enter into Distribution Agreement for Afrezza in Brazil